48 (Fig 3) .
Moreover, in the no-nitrates group, the percent increase in platelet cGMP levels was significantly correlated with the percent dilatation of the coronary arteries (platelet cGMP from artery and coronary diameter: left anterior descending, r=.90, P<.01; left circumflex, r=.92, P<.01) (Fig 4) . Similar 
Effects of Nitroglycerin on Epicardial
Coronary Artery Intracoronary administration of nitroglycerin induced a consistent and pronounced vasodilation of the epicardial coronary arteries that was less pronounced in the nitrates group than in the no-nitrates group. This difference between the two groups was similar to the difference in the percent increase in platelet cGMP after nitroglycerin injection. In an in vitro experimental study, the relaxant effect of nitroglycerin has been significantly correlated with the increase in the cGMP levels in the vessels. 47 Thus, our results indicate that in patients administered nitrates, intracellular cGMP production in the response to nitroglycerin injection was impaired. However, there were some limitations in the relation between the coronary dilatation and platelet cGMP levels. As shown in Fig 4, Wei and Reid62 have shown that plasma nitroglycerin levels were maximal at 2 minutes after sublingual administration of 0.6 mg nitroglycerin, when the changes in mean heart rate and systolic pressure were also maximal. In our preliminary studies (not published), we measured platelet cGMP in six patients with chest pain syndrome at 30 seconds and 1, 2, and 3 minutes after intracoronary injection of 200 jig nitroglycerin and found maximal levels at 2 and 3 minutes. Armstrong and coworkers60 also suggested injection of 200 jig nitroglycerin was both safe and sufficient to produce a minimum effective blood level. Bohme and coworkers35 have reported in their in vitro study that sodium nitroprusside increased cGMP in smooth muscle and platelet within 1 minute and that this effect was not significantly changed over 10 minutes. On the basis of these data, we chose 2 minutes after nitroglycerin injection as a timing of blood sampling and 200 g.g as a dose of nitroglycerin.
Second, the possible contribution of cGMP degradation was not investigated in this study. A potential nitrate effect on cGMP degradation may be an important mechanism on nitrate tolerance. In our results, there was no difference in platelet cGMP levels before the injection of nitroglycerin between the nitrate and no-nitrate groups. Thus, it might be speculated that not only the production of platelet cGMP but also cGMP degradation increased in the nitrated group and that cGMP levels had kept their balance in platelet.
Third, in our study, 10 of the 15 patients in the nitrate group had been receiving calcium channel blockers until 48 hours before the study. Intracellular calcium increase is necessary for physiological platelet activity, particularly relating to aggregation. Calcium channel blockers have been known to inhibit platelet aggregation.63 '4 Although the effect of nitroglycerin on the platelet aggregation was not investigated in this study, the results observed in the nitrate group might have been partially contaminated by a drug-drug interaction involving the calcium channel blockers.
Fourth, the issue of selection of patients for the present study relates to the final limitation. There were the substantial differences in the disease diagnosis between the nitrate and no-nitrate groups. This difference in patient composition might confound interpretation of the results.
Conclusion
In this study, we investigated platelet cGMP levels before and after the injection of nitroglycerin in 15 patients who had previously received nitrates and in 16 patients who had not. Platelet cGMP levels increased significantly after nitroglycerin injection in the two groups, but the percent increase in platelet cGMP levels was significantly higher in the no-nitrates group than in the nitrates group. The percent dilatation of coronary arteries after nitroglycerin injection was also significantly higher in the no-nitrates group than in the nitrates group. These results indicate that platelet cGMP can be a potentially useful indicator to evaluate the effects of nitroglycerin in vivo and that patients in the nitrates group had developed tolerance, which affects intracellular production of cGMP in response to nitroglycerin.
